Ohcanbohtosat - Alain Baron
- Čájehuvvo 1 - 20 / 24
- Sirdás čuovvovaš siidui
-
1
Improving apple juice expression and quality by pulsed electric field on an industrial scale Dahkki Mohammad Turk, Eugène Vorobiev, Alain Baron
Almmustuhtton 2012Artigo -
2
Insulin resistance in the vasculature Dahkki Kieren J. Mather, Helmut O. Steinberg, Alain Baron
Almmustuhtton 2013Carta -
3
Endothelin Limits Insulin Action in Obese/Insulin-Resistant Humans Dahkki Amale Lteif, Prashant Vaishnava, Alain Baron, Kieren J. Mather
Almmustuhtton 2007Artigo -
4
-
5
Antiobesity Effects of the β-Cell Hormone Amylin in Diet-Induced Obese Rats: Effects on Food Intake, Body Weight, Composition, Energy Expenditure, and Gene Expression Dahkki Jonathan D. Roth, Heather Hughes, Eric S. Kendall, Alain Baron, Christen M. Anderson
Almmustuhtton 2006Artigo -
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure Dahkki Que Liu, Christen M. Anderson, Anatoly Broyde, Clara J. Polizzi, Rayne Fernandez, Alain Baron, David G. Parkes
Almmustuhtton 2010Artigo -
15
Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials Dahkki Ralph A. DeFronzo, John B. Buse, Terri Kim, Colleen Burns, Sharon Skare, Alain Baron, Mark Fineman
Almmustuhtton 2016Artigo -
16
Effect on Glycemic Control of Exenatide (Synthetic Exendin-4) Additive to Existing Metformin and/or Sulfonylurea Treatment in Patients With Type 2 Diabetes Dahkki Mark Fineman, Thomas A. Bicsak, Larry Z. Shen, Kristin Taylor, Eling Gaines, Amanda Varns, Dennis Kim, Alain Baron
Almmustuhtton 2003Artigo -
17
Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea Dahkki David M. Kendall, Matthew C. Riddle, Julio Rosenstock, Dongliang Zhuang, Dennis Dong Hwan Kim, Mark Fineman, Alain Baron
Almmustuhtton 2005Artigo -
18
The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies Dahkki John B. Buse, Ralph A. DeFronzo, Julio Rosenstock, Terri Kim, Colleen Burns, Sharon Skare, Alain Baron, Mark Fineman
Almmustuhtton 2015Artigo -
19
-
20
Ohcanreaiddut:
Laktáseaddji fáttát
Endocrinology
Internal medicine
Medicine
Diabetes mellitus
Insulin
Type 2 diabetes
Insulin resistance
Exenatide
Alternative medicine
Pathology
Placebo
Gastroenterology
Biology
Obesity
Receptor
Vasodilation
Blood pressure
Endothelial dysfunction
Glycemic
Islet
Metformin
Postprandial
Adverse effect
Amylin
Biochemistry
Chemistry
Endothelin receptor
Endothelium
Gastric emptying
Pharmacology